NICE issues early 'no' on RoActemra, Rydapt by Carly Helfand Wednesday, December 6, 2017 Two Swiss pharma giants got some news out of England Tuesday that they weren’t too excited about.
Roche nets new Actemra nod to treat deadly CAR-T response by Carly Helfand Friday, September 1, 2017 Roche’s Actemra has a new use and it’s an important one—both for the med’s own sales and for expansion of the brand-new CAR-T market.
AbbVie's Humira needs a big price cut, ICER says by Tracy Staton Monday, April 10, 2017 The world's best-selling drug, AbbVie's Humira, isn’t worth its current net price—and isn’t as good at its job as two potential competitors. That’s ICER's conclusion after reviewing rheumatoid arthritis meds.
